Company Overview of Iroko Pharmaceuticals, LLC
Iroko Pharmaceuticals, LLC, a specialty pharmaceutical company, develops and commercializes pharmaceutical products. It focuses on treatment options to address patient needs in pain management. The company markets and distributes Indocid (indomethacin) capsules and suppositories; Aldomet (methyldopa) tablets; TIVORBEX (indomethacin) capsules; ZORVOLEX, a nonsteroidal anti-inflammatory drug for the management of osteoarthritis pain and for the treatment of mild to moderate acute pain in adults; and VIVLODEX (meloxicam) capsules, a nonsteroidal anti-inflammatory drug for the management of osteoarthritis pain. It markets and sells its products through distribution and sales network in the Unite...
One Kew Place
150 Rouse Boulevard
Philadelphia, PA 19112
Founded in 2007
Key Executives for Iroko Pharmaceuticals, LLC
Chief Executive Officer, President and Director
Founder and Chairman of the Board
Chief Financial Officer and Senior Vice President
Senior Vice President and General Counsel
Senior Vice President of Commercial Operations - Europe & International
Compensation as of Fiscal Year 2016.
Iroko Pharmaceuticals, LLC Key Developments
Iroko Pharmaceuticals LLC Provides Update in Relation to Zorvolex
Dec 7 16
Iroko Pharmaceuticals LLC provided an update in relation to its novel Zorvolex® Capsules 18 mg and 35 mg. Iroko has been advised that the United States Food and Drug Administration (FDA) has tentatively approved Lupin Pharmaceuticals Inc.'s, Abbreviated New Drug Application (ANDA) for its Diclofenac Capsules, 18 mg and 35 mg to market a generic version of Iroko's, Zorvolex® Capsules 18 mg and 35 mg. Iroko has and will continue to vigorously defend the several patents and regulatory rights that protect Zorvolex®. Zorvolex® has US regulatory market exclusivity for the management of osteoarthritis pain until August 2017. Iroko is committed to defending the IP protecting Zorvolex® to the fullest extent of the law.
Iroko Pharmaceuticals, LLC Presents at Life Sciences Summit 2016, Nov-03-2016 11:00 AM
Oct 27 16
Iroko Pharmaceuticals, LLC Presents at Life Sciences Summit 2016, Nov-03-2016 11:00 AM. Venue: 10 on the Park at Time Warner Center, 60 Columbus Circle 10th Floor, New York, NY 10019, United States. Speakers: Kate de Santis, Vice President of Investor Relations.
Iroko Pharmaceuticals, LLC Announces Executive Changes
Jul 11 16
Iroko Pharmaceuticals, LLC announced the appointment of Louis J. Vollmer as President and Chief Executive Officer effective July 6, 2016. Mr. Vollmer has been serving as President of Iroko since March 2015 and continues as a member of Iroko's Board of Directors, which he joined in February 2014. He succeeds Osagie Imasogie, Iroko's Founder, as CEO; Mr. Imasogie will remain Iroko's Chairman. Mr. Vollmer will oversee the day-to-day operations and long term strategic planning of Iroko, focusing on maximizing the potential of Iroko's SoluMatrix® franchise brands, expanding the company's global presence and creating and acquiring innovative treatment options for responsible pain management.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 29, 2016